Vascular access thrombosis prophylaxis

Seminars in Dialysis

Volumn 19, Issue 4, 2006, Pages 335-342

  Choudhury, Devasmita ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIOVENOUS SHUNT; HUMAN; INDWELLING CATHETER; RENAL REPLACEMENT THERAPY; REVIEW; THROMBOSIS; VASCULAR PATENCY;

ARTERIOVENOUS SHUNT, SURGICAL; CATHETERS, INDWELLING; HUMANS; RENAL DIALYSIS; THROMBOSIS; VASCULAR PATENCY;

EID: 33746216751     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00182.x     Document Type: Review

References (104)

1. National Kidney Foundation: NKF-K/DOQI clinical practice guidelines for vascular access. Am J Kidney Dis 37:S169, 2001
2. Schwab SJ, Raymond JR, Saeed M, Newman GE, Dennis PA, Bollinger RR: Prevention of hemodialysis fistula thrombosis. Early detection of venous stenoses. Kidney Int 36:707-711, 1989
3. Sands J, Young S, Miranda C: The effect of Doppler flow screening studies and elective revisions on dialysis access failure. ASAIO J 38:M524-M527, 1992
4. Tessitore N, Bedogna V, Gammaro L, Lipari G, Poli A, Baggio E, Firpo M, Morana G, Mansueto G, Maschio G: Diagnostic accuracy of ultrasound dilution access blood flow measurement in detecting stenosis and predicting thrombosis in native forearm arteriovenous fistulae for hemodialysis. Am J Kidney Dis 42:331-341, 2003
5. Neyra NR, Ikizler TA, May RE, Himmelfarb J, Schulman G, Shyr Y, Hakim RM: Change in access blood flow over time predicts vascular access thrombosis. Kidney Int 54:1714-1719, 1998
6. Tynan-Cuisiner G, Berman SS: Advances in endovascular techniques to treat failing and failed hemodialysis access. J Endovasc Ther 11(suppl 2):II134-II139, 2004
7. Sands JJ, Miranda CL: Prolongation of hemodialysis access survival with elective revision. Clin Nephrol 44:329-333, 1995
8. Oliver MJ, McCann RL, Indridason OS, Butterly DW, Schwab SJ: Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas. Kidney Int 60:1532-1539, 2001
9. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC: Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 80:1726-1736, 1989
10. Woods JD, Turenne MN, Strawderman RL, Young EW, Hirth RA, Port FK, Held PJ: Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis 30:50-57, 1997
11. Ascher E, Gade P, Hingorani A, Mazzariol F, Gunduz Y, Fodera M, Yorkovich W: Changes in the practice of angioaccess surgery: impact of dialysis outcome and quality initiative recommendations. J Vasc Surg 31:84-92, 2000
12. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 7:523-535, 1996
13. Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD, Meyer K, Beasley D: Vascular access for hemodialysis. Kidney Int 55:2078-2090, 1999
14. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M: Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 36:68-74, 2000
15. Hodges TC, Fillinger MF, Zwolak RM, Walsh DB, Bech F, Cronenwett JL: Longitudinal comparison of dialysis access methods: risk factors for failure. J Vasc Surg 26:1009-1019, 1997
16. Allon M, Bailey R, Ballard R, Deierhoi MH, Hamrick K, Oser R, Rhynes VK, Robbin ML, Saddekni S, Zeigler ST: A multidisciplinary approach to hemodialysis access: prospective evaluation. Kidney Int 53:473-479, 1998
17. Hemphill H, Allon M, Konner K, Work J, Vassalotti JA: How can the use of arteriovenous fistulas be increased? Semin Dial 16:214-223, 2003
18. Berman SS, Gentile AT: Impact of secondary procedures in autogenous arteriovenous fistula maturation and maintenance. J Vasc Surg 34:866-871, 2001
19. Gormus N, Ozergin U, Durgut K, Yuksek T, Solak H: Comparison of autologous basilic vein transpositions between forearm and upper arm regions. Ann Vasc Surg 17:522-525, 2003
20. Segal JH, Kayler LK, Henke P, Merion RM, Leavey S, Campbell DA Jr: Vascular access outcomes using the transposed basilic vein arteriovenous fistula. Am J Kidney Dis 42:151-157, 2003
21. Murphy GJ, White SA, Knight AJ, Doughman T, Nicholson ML: Long-term results of arteriovenous fistulas using transposed autologous basilic vein. Br J Surg 87:819-823, 2000
22. Taghizadeh A, Dasgupta P, Khan MS, Taylor J, Koffman G: Long-term outcomes of brachiobasilic transposition fistula for haemodialysis. Eur J Vasc Endovasc Surg 26:670-672, 2003
23. Rao RK, Azin GD, Hood DB, Rowe VL, Kohl RD, Katz SG, Weaver FA: Basilic vein transposition fistula: a good option for maintaining hemodialysis access site options? J Vasc Surg 39:1043-1047, 2004
24. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 330:1431-1438, 1994
25. Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, Heffelfinger SC: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 59:2325-2334, 2001
26. Vaziri ND, Gonzales EC, Wang J, Said S: Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 23:828-835, 1994
27. Mysliwiec M: Vascular access thrombosis - what are the possibilities of intervention? Nephrol Dial Transplant 12:876-878, 1997
28. Weiss MF, Scivittaro V, Anderson JM: Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis 37:970-980, 2001
29. Heine GH, Ulrich C, Sester U, Sester M, Kohler H, Girndt M: Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int 64:1101-1107, 2003
30. Ross R, Glomset J, Kariya B, Harker L: A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 71:1207-1210, 1974
31. Chuang YC, Chen JB, Yang LC, Kuo CY: Significance of platelet activation in vascular access survival of haemodialysis patients. Nephrol Dial Transplant 18:947-954, 2003
32. Casserly LF, Dember LM: Thrombosis in end-stage renal disease. Semin Dial 16:245-256, 2003
33. Masood I, Porter KE, London NJ: Endothelin-1 is a mediator of intimal hyperplasia in organ culture of human saphenous vein. Br J Surg 84:499-503, 1997
34. Wilkie ME, Khandan-Nia N, Ghatei MA, Bloom SR, Raftery MJ, Cunningham J: Does the arteriovenous fistula in chronic haemodialysis patients stimulate endothelin-1 release? Nephrol Dial Transplant 7:1019-1021, 1992
35. Sapienza P, di Marzo L, Cucina A, Corvino V, Mingoli A, Giustiniani Q, Ziparo E, Cavallaro A: Release of PDGF-BB and bFGF by human endothelial cells seeded on expanded polytetrafluoroethylene vascular grafts. J Surg Res 75:24-29, 1998
36. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68:450-456, 1991
37. Rotmans JI, Pasterkamp G, Verhagen HJ, Pattynama PM, Blankestijn PJ, Stroes ES: Hemodialysis access graft failure: time to revisit an unmet clinical need? J Nephrol 18:9-20, 2005
38. Angelini GD, Christie MI, Bryan AJ, Lewis MJ: Surgical preparation impairs release of endothelium-derived relaxing factor from human saphenous vein. Ann Thorac Surg 48:417-420, 1989
39. Vaziri ND: Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 38:S74-S79, 2001
40. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105:1890-1896, 2002
41. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107:87-92, 2003
42. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Giovannini L, Norpoth M, Metelli MR, Cristofani R, Bertelli AA, Sbragia G, Tetta C, Palla R, Colombo R: C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 91:594-600, 2002
43. Mezzano D, Pais EU, Aranda E, Panes O, Downey P, Ortiz M, Tagle R, Gonzalez F, Quiroga T, Caceres MS, Leighton F, Pereira J: Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60:1844-1850, 2001
44. Halwachs G, Tiran A, Reisinger EC, Zach R, Sabin K, Folsch B, Lanzer H, Holzer H, Wilders-Truschnig M: Serum levels of the soluble receptor for tumor necrosis factor in patients with renal disease. Clin Invest 72:473-476, 1994
45. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH: Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 16:1189-1197, 2001
46. Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P, Cartier P, Fay WP, Goldstein MB, Jindal K, Mandin H, et al.: Canadian hemodialysis morbidity study. Am J Kidney Dis 19:214-234, 1992
47. Kalman PG, Pope M, Bhola C, Richardson R, Sniderman KW: A practical approach to vascular access for hemodialysis and predictors of success. J Vasc Surg 30:727-733, 1999
48. Kaysen GA: The microinflammatory state in uremia, causes and potential consequences. J Am Soc Nephrol 12:1549-1557, 2001
49. Kaysen GA, Stevenson FT, Depner TA: Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 29:658-668, 1997
50. Becker BN, Himmelfarb J, Henrich WL, Hakim RM: Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8:475-486, 1997
51. Roselaar SE, Nazhat NB, Winyard PG, Jones P, Cunningham J, Blake DR: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 48:199-206, 1995
52. Segarra A, Chacon P, Martinez-Eyarre C, Argelaguer X, Vila J, Ruiz P, Fort J, Bartolome J, Camps J, Moliner E, Pelegri A, Marco F, Olmos A, Piera L: Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 12:1255-1263, 2001
53. Molino D, Lucia D, Marotta R, Perna A, Lombardi C, Cirillo M, De Santo NG: In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 68:1223-1229, 2005
54. Garcia-Martin F, De Arriba G, Carrascosa T, Moldenhauer F, Martin-Escobar E, Val J, Saiz F: Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant 6:543-547, 1991
55. Gronhagen-Riska C, Teppo AM, Helantera A, Honkanen E, Julkunen H: Raised concentrations of antibodies to cardiolipin in patients receiving dialysis. Br Med J 300:1696-1697, 1990
56. Haviv YS: Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: cause or effect? Nephron 86:447-454, 2000
57. Brunet P, Aillaud MF, San Marco M, Philip-Joet C, Dussol B, Bernard D, Juhan-Vague I, Berland Y: Antiphospholipids in hemodialysis patients. relationship between lupus anticoagulant and thrombosis. Kidney Int 48:794-800, 1995
58. Prakash R, Miller CC 3rd, Suki WN: Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 26:347-352, 1995
59. Fodinger M, Mannhalter C, Pabinger I, Koizar D, Rintelen C, Horl WH, Sunder-Plassmann G: Resistance to activated protein C (APC). mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Transplant 11:668-672, 1996
60. Shemin D, Lapane KL, Bausserman L, Kanaan E, Kahn S, Dworkin L, Bostom AG: Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol 10:1095-1099, 1999
61. McCarley P, Wingard RL, Shyr Y, Pettus W, Hakim RM, Ikizler TA: Vascular access blood flow monitoring reduces access morbidity and costs. Kidney Int 60:1164-1172, 2001
62. Besarab A, Frinak S, Sherman RA, Goldman J, Dumler F, Devita MV, Kapoian T, Al-Saghir F, Lubkowski T: Simplified measurement of intra-access pressure. J Am Soc Nephrol 9:284-289, 1998
63. Besarab A, Sullivan KL, Ross RP, Moritz MJ: Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis. Kidney Int 41:1364-1373, 1995
64. Choudhury D, Lee J, Elivera HS, Ball D, Roberts AB, Ahmed Z: Correlation of venography, venous pressure, and hemoaccess function. Am J Kidney Dis 25:269-275, 1995
65. Paun M, Beach K, Ahmad S, Hickman R, Meissner M, Plett C, Strandness DE Jr: New ultrasound approaches to dialysis access monitoring. Am J Kidney Dis 35:477-481, 2000
66. Dousset V, Grenier N, Douws C, Senuita P, Sassouste G, Ada L, Potaux L: Hemodialysis grafts: color Doppler flow imaging correlated with digital subtraction angiography and functional status. Radiology 181:89-94, 1991
67. Robbin ML, Oser RF, Allon M, Clements MW, Dockery J, Weber TM, Hamrick-Waller KM, Smith JK, Jones BC, Morgan DE, Saddekni S: Hemo-dialysis access graft stenosis: US detection. Radiology 208:655-661, 1998
68. Dember LM, Holmberg EF, Kaufman JS: Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosis. Kidney Int 66:390-398, 2004
69. Shahin H, Reddy G, Sharafuddin M, Katz D, Franzwa BS, Dixon BS: Monthly access flow monitoring with increased prophylactic angioplasty did not improve fistula patency. Kidney Int 68:2352-2361, 2005
70. Beathard GA: Percutaneous transvenous angioplasty in the treatment of vascular access stenosis. Kidney Int 42:1390-1397, 1992
71. Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D: Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty. Radiology 195:135-139, 1995
72. Gallego Beuter JJ, Hernandez Lezana A, Herrero Calvo J, Moreno Carriles R: Early detection and treatment of hemodialysis access dysfunction. Cardiovasc Intervent Radiol 23:40-46, 2000
73. Masaki T, Rathi R, Zentner G, Leypoldt JK, Mohammad SF, Burns GL, Li L, Zhuplatov S, Chirananthavat T, Kim SJ, Kern S, Holman J, Kim SW, Cheung AK: Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int 66:2061-2069, 2004
74. Dammers R, Planken RN, Pouls KP, Van Det RJ, Burger H, Van Der Sande FM, Tordoir JH: Evaluation of 4-mm to 7-mm versus 6-mm prosthetic brachial-antecubital forearm loop access for hemodialysis: results of a randomized multicenter clinical trial. J Vasc Surg 37:143-148, 2003
75. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM: Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 45:1477-1483, 1994
76. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW: Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 40:1255-1263, 2002
77. Kobayashi K, Maeda K, Koshikawa S, Kawaguchi Y, Shimizu N, Naito C: Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis - a multicenter collaborative double blind study. Thromb Res 20:255-261, 1980
78. Domoto DT, Bauman JE, Joist JH: Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thromb Res 62:737-743, 1991
79. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, Goldfarb DS, Peduzzi PN: Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14:2313-2321, 2003
80. Cartwright IJ, Pockley AG, Galloway JH, Greaves M, Preston FE: The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis 55:267-281, 1985
81. Fox PL, DiCorleto PE: Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein. Science 241:453-456, 1988
82. Shiina T, Terano T, Saito J, Tamura Y, Yoshida S: Eicosapentaenoic acid and docosahexaenoic acid suppress the proliferation of vascular smooth muscle cells. Atherosclerosis 104:95-103, 1993
83. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME: Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol 13:184-190, 2002
84. Gradzki R, Dhingra RK, Port FK, Roys E, Weitzel WF, Messana JM: Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 38:1240-1244, 2001
85. Choudhury D: ACE-inhibitors prolong PTFE graft survival in hemodialysis patients. J Am Soc Nephrol 11:182A, 2000
86. Sone M: Angiotensin II inhibition prevents the occlusion of arterio-venous fistula in hemodialysis patients: a prospective case-control study. J Am Soc Nephrol 11:197A, 2000
87. Diskin CJ, Stokes TJ, Thomas SG, Ravis W, Lock S, Thomas J, Panus LW, Dansby L, Carter T: An analysis of the effect of routine medications on hemodialysis vascular access survival. Nephron 78:365-368, 1998
88. Knoll GA, Wells PS, Young D, Perkins SL, Pilkey RM, Clinch JJ, Rodger MA: Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol 16:1108-1114, 2005
89. O'Shea SI, Lawson JH, Reddan D, Murphy M, Ortel TL: Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 38:541-548, 2003
90. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW: Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 55:315-320, 1999
91. Sirrs S, Duncan L, Djurdjev O, Nussbaumer G, Ganz G, Frohlich J, Levin A: Homocyst(e)ine and vascular access complications in haemodialysis patients: insights into a complex metabolic relationship. Nephrol Dial Transplant 14:738-743, 1999
92. Hojs R, Gorenjak M, Ekart R, Dvorsak B, Pecovnik-Balon B: Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail 24:215-222, 2002
93. Mallamaci F, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Candela V, Scudo P, Spoto B, Testa A, Tripepi G, Tech S, Zoccali C: Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis 45:702-707, 2005
94. Jamison RL, Hartigan P, Gaziano JM, Fortmann SP, Goldfarb DS, Haroldson JA, Kaufman J, Lavori P, McCully KS, Robinson K: Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. Clin Trials 1:451-460, 2004
95. Rotmans JI, Velema E, Verhagen HJ, Blankensteijn JD, de Kleijn DP, Stroes ES, Pasterkamp G: Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg 39:432-439, 2004
96. Schopohl B, Leirmann D, Pohlit LJ, Heyd R, Strassmann G, Bauersachs R, Schulte-Huermann D, Rahl CG, Manegold KH, Kollath J, Bottcher HD: 192Ir endovascular brachytherapy for avoidance of intimal hyperplasia after percutaneous transluminal angioplasty and stent implantation in peripheral vessels: 6 years of experience. Int J Radiat Oncol Biol Phys 36:835-840, 1996
97. Trerotola SO, Carmody TJ, Timmerman RD, Bergan KA, Dreesen RG, Frost SV, Forney M: Brachytherapy for the prevention of stenosis in a canine hemodialysis graft model: preliminary observations. Radiology 212:748-754, 1999
98. Roy-Chaudhury P, Duncan H, Barrett W, Elson H, Narayana A, Foley J, Misra S, Lynch PM, Zuckerman D: Vascular brachytherapy for hemodialysis vascular access dysfunction: exploring an unmet clinical need. J Invasive Cardiol 15(suppl A):25A-30A, 2003
99. Barton J, Nielsen H, Rychnovsky S, Farooq M, Freischlag J, Grove R: PhotoPoint photodynamic therapy inhibits intimal hyperplasia in arteriovenous access grafts. Cardiovasc Radiat Med 3:147-151, 2002
100. Rotmans JI, Verhagen HJ, Velema E, de Kleijn DP, van den Heuvel M, Kastelein JJ, Pasterkamp G, Stroes ES: Local overexpression of C-type natriuretic peptide ameliorates vascular adaptation of porcine hemodialysis grafts. Kidney Int 65:1897-1905, 2004
101. Fuster V, Charlton P, Boyd A: Clinical protocol: a phase IIb, randomized, multicenter, double-blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft-vein anastomosis site in dialysis patients. Hum Gene Ther 12:2025-2027, 2001
102. Cheng L, Mantile G, Pauly R, Nater C, Felici A, Monticone R, Bilato C, Gluzband YA, Crow MT, Stetler-Stevenson W, Capogrossi MC: Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 98:2195-2201, 1998
103. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH: Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 101:296-304, 2000
104. Kibbe MR, Tzeng E, Gleixner SL, Watkins SC, Kovesdi I, Lizonova A, Makaroun MS, Billiar TR, Rhee RY: Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 34:156-165, 2001